BiotechTube
Home/Pipeline/SHR-1905

SHR-1905

Hematologic malignancies

Phase 1Active

Key Facts

Indication
Hematologic malignancies
Phase
Phase 1
Status
Active
Company
Jiangsu Hengrui Medicine

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd. is a leading Chinese pharmaceutical company founded in 1970, headquartered in Lianyungang, Jiangsu Province. The company has evolved from producing generic drugs to becoming a major innovator in oncology, with particular strength in developing novel cancer treatments, anesthesia drugs, and medical imaging contrast agents. Hengrui has established itself as one of China's most valuable pharmaceutical companies with significant R&D investments and an expanding global footprint.

View full company profile

Therapeutic Areas

OncologyAnesthesiaContrast ImagingPain ManagementHematology

Other Hematologic malignancies Drugs

DrugCompanyPhase
Rituximab biosimilar (IBI301)Innovent BiologicsApproved
Alemtuzumab BiosimilarCSPC Pharmaceutical Group LimitedPhase 3
Lead CAR-T ProgramArcellxPhase 1
KT-333Kymera TherapeuticsPhase 1
Undisclosed CAR-T programsBeam TherapeuticsDiscovery/Preclinical
NX-1607Nurix TherapeuticsPhase 1a
Trichostatin A (TSA)Vanda PharmaceuticalsOncology Program
Cord Blood HSC UnitGlobal Cord BloodApproved/Commercial
TSC-102-A01TScan TherapeuticsPreclinical
TSC-102-A03TScan TherapeuticsPreclinical
LBL-007LakeShore BiopharmaPhase 1
CER-T Cell PlatformCERo TherapeuticsPre-clinical